SciBase Secures Financial Backing Through Guarantee Commitment for Rights Issue

On September 25, 2026, SciBase Holding AB (publ), known simply as SciBase, announced an important development regarding its ongoing rights issue. The company has successfully met its commitment to secure a guarantee from Bergs Securities AB, fulfilling a letter of intent disclosed earlier on September 3, 2026. This guarantee is a pivotal element in the company’s rights issue, aimed at raising approximately SEK 57.5 million. The financial backing from Bergs Securities amounts to about SEK 24.2 million, accounting for approximately 42% of the total sought in the rights issue.

In conjunction with existing subscription agreements aggregating to around SEK 33.3 million—covering the remaining 58%—SciBase now boasts 100% backing for its rights issue, vital for its business operations and continued innovation. The guarantee commitment signifies that Bergs Securities has pledged to subscribe for any shares that are left unsubscribed in the rights issue, facilitating better capital flow for SciBase.

The initiative follows a clear timeline for subscription and trading of shares in the rights issue. The subscription price is set at SEK 15 per share. For shareholders listed on the share register maintained by Euroclear Nordics AB as of the record date on September 10, 2026, each will receive one subscription right for each share held, allowing holders of eight subscription rights to acquire three new shares. The subscription period commenced on September 15, 2026, and will run until September 29, 2026. Furthermore, Nasdaq First North Growth Market allowed trading in subscription rights until September 24, 2026. Trading for paid subscribed shares continues until around October 16, 2026, while results from the rights issue should be announced around October 1, 2026.

Amidst these developments, several existing shareholders, including major entities like Castle Biosciences Inc and Life Science Invest Fund 1 ApS, have already confirmed their participation by entering subscription undertakings that bolster the funding significantly. Interestingly, these commitments do not require collateral in the format of bank guarantees or blocked funds, exemplifying a vote of confidence in SciBase’s business model and future.

SciBase operates at the forefront of dermatological technology, utilizing artificial intelligence and advanced electrical impedance spectroscopy (EIS) methodologies in its flagship product, Nevisense. This approach provides healthcare professionals with enhanced capabilities to detect skin conditions early, ultimately aiming to improve patient outcomes while driving down overall healthcare costs.

The involvement of Bergs Securities extends beyond mere financial backing; they, along with Birchtree Advisory, provide crucial advisory services for the rights issue. BAHR, a legal advisor involved in this process, ensures that all compliances and regulatory requirements are met as SciBase navigates this capital growth strategy.

This strategic move comes as part of SciBase’s broader objectives to enhance its operational framework and continue its mission in advancing medical technology aimed at skin health. With an established history of over 20 years of dedication to research from the esteemed Karolinska Institutet in Sweden, SciBase remains committed to minimizing patient suffering and improving lives through proactive skin health management.

As SciBase forges ahead in this new chapter of enhanced financial stability and operational growth, it eagerly anticipates the results of the rights issue that could potentially propel its innovations in dermatology to new heights.

For further updates, interested parties can refer to the dedicated information document available on SciBase’s investor relations website. This resource provides comprehensive details about the rights issue and related developments, reaffirming SciBase’s transparency and commitment towards its stakeholders.